Form 4: KalVista CDO Exercises RSUs, Sells Shares for Tax

KalVista Pharmaceuticals' Chief Development Officer, Christopher Yea, acquired 3,125 shares through RSU vesting and subsequently sold 1,954 shares to cover tax obligations.

Summary

• Christopher Yea, Chief Development Officer of KalVista Pharmaceuticals, Inc., reported transactions involving the company's common stock.
• On August 22, 2025, Yea acquired 3,125 shares of common stock through the vesting and settlement of Restricted Stock Units (RSUs).
• Following this acquisition, Yea beneficially owned 134,006 shares of common stock directly.
• On August 25, 2025, Yea sold 1,954 shares of common stock at a price of $13.42 per share.
• This sale was explicitly stated as a 'sell to cover' transaction to satisfy tax withholding obligations related to the RSU vesting and was not a discretionary sale.
• After the sale, Yea's direct beneficial ownership of common stock decreased to 132,052 shares.
• Each RSU represents a contingent right to receive one share of common stock upon settlement for no consideration.
• The RSUs vest quarterly, with 1/16th of the total number of shares underlying the RSUs vesting on each quarterly anniversary of the Vesting Commencement Date.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. The RSU vesting is a positive for the executive, indicating ongoing compensation. The subsequent sale is a non-discretionary 'sell to cover' for tax purposes, which is a neutral event and not indicative of a negative outlook by the insider.

Positives

• The vesting of 3,125 Restricted Stock Units (RSUs) represents a compensation benefit for the Chief Development Officer, increasing their direct ownership before the tax-related sale.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This Form 4 filing details an individual insider transaction, which is a routine disclosure for executive compensation and does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: The sale of 1,954 shares represents a minor, non-discretionary dilution, which is generally not significant enough to impact the broader shareholder base.
• Employees (specifically Christopher Yea): The RSU vesting and subsequent tax-related sale are part of the executive's compensation package, providing liquidity for vested equity.

Key Dates

Keywords

KalVista Pharmaceuticals, KALV, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Sell to Cover, Tax Withholding, Beneficial Ownership, Chief Development Officer